Literature DB >> 9265905

Mild liver enzyme abnormalities: eliminating hemochromatosis as cause.

D L Witte1.   

Abstract

Chronic mild liver enzyme abnormalities are attributable to hereditary hemochromatosis in at least 3% of cases. Hemochromatosis formerly was diagnosed late with diabetes and hepatic and cardiac failure. Only recently have the autosomal recessive inheritance and subtle early presentations been understood. However, patients still wait many years and see many physicians before receiving a correct diagnosis. Increased serum transferrin saturation is currently the best test for detection of those likely to accumulate iron. Serum ferritin identifies those requiring treatment. When liver biopsy (controversial in asymptomatic individuals) is indicated, chemical measurement of liver iron content is helpful and therapeutic phlebotomy is the only effective treatment. Caucasian-type hemochromatosis (prevalence of 0.005) is associated with genetic abnormalities in HLA-H but also occurs in other ethnic groups. Those of African descent may have a different but also heritable iron-loading disease. Caucasian-type and to a lesser extent African iron loading are detectable early by laboratory testing. Early treatment restores normal expectations of length and quality of life in the Caucasian disease. Long-term treatment data are not yet available in African iron loading. Laboratory-initiated screening programs using unsaturated iron-binding capacity can eliminate symptomatic hemochromatosis.

Entities:  

Mesh:

Year:  1997        PMID: 9265905

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase.

Authors:  M Bhavnani; D Lloyd; A Bhattacharyya; J Marples; P Elton; M Worwood
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

Review 2.  Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring.

Authors:  D R Dufour; J A Lott; F S Nolte; D R Gretch; R S Koff; L B Seeff
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.